SUMMARY
INTRODUCTION
Cell differentiation is a complex process regulated by an interplay between intrinsic cellular programs, cell-cell and cell-substrate interactions and a plethora of soluble extra-cellular signaling molecules, including hormones, growth factors, cytokines, trophic factors, morphogens, etc. Retinoic Acid (RA) 1 , the biologically active form of vitamin A, plays important role in early embryonic development and in the generation of several organs and systems, like it is the case of the nervous system (1-3, for review). In vitro, RA also plays a prominent role in regulating the transition from the proliferating precursor cell to the post-mitotic differentiated cell, and there are many examples in the literature of distinct cell types whose differentiation is under the control of RA (4) (5) (6) (7) (8) (9) (10) .
Two types of receptors, the RARs and the RXRs (11) mediate RA signaling. These receptors belong to the superfamily of the Nuclear Hormone Receptors, which function as ligandregulated transcription factors, and act modifying the transcriptional activity of specific genes (12, 13 , for review). To elucidate the molecular mechanisms through which RA induces differentiation of neural cells, we have analyzed the changes in gene expression associated with RA-induced differentiation using human neuroblastoma cells as a model system. Neuroblastoma is a childhood tumor that arises from neural crest neuroectodermal cells (14, 15 , for review).
Despite their tumoral origin, neuroblastoma cell lines can be induced to differentiate in vitro by several agents, including RA (7, (16) (17) (18) . In vitro differentiated neuroblastoma cells have a neuronal phenotype, as judged by their morphology and the expression of biochemical and functional neuronal markers. Therefore, neuroblastoma cells could be considered as an useful model system to study the initial phases of neuronal differentiation (19) . RA derivatives are being employed in the therapy of neuroblastoma, and neuroblastoma patients treated with RA have increased survival rates (20, 21) . Nevertheless, little is known about the molecular basis of the therapeutic effects of RA on neuroblastoma tumors. 4 Here we show that RA treatment of SH-SY5Y human neuroblastoma cells leads to changes in the expression levels of bHLH transcription factors, a gene family involved in the regulation of lineage commitment and cell differentiation in many cell types (22, for review). The products of ID genes act as dominant-negative inhibitors of differentiation by avoiding the binding of other bHLH transcription factors to their cognate DNA elements named E-boxes. RA treatment of SH-SY5Y neuroblastoma cells leads to a coordinated downregulation of the differentiation-inhibiting ID1, ID2 and ID3 genes. In addition, the expression of the neuroblastspecific bHLH transcription factor ASCL1 (HASH-1) is rapidly reduced, and the mRNA levels of the differentiation-promoting bHLH factors NEUROD6 and NEUROD1 are increased. These results support the idea that RA treatment may induce differentiation by altering the balance between differentiation-inhibiting and differentiation-promoting bHLH factors.
The mechanism through which RA downregulates the ID gene expression appeared to be complex, since repression required newly synthesized proteins and the activity of Phosphatidyl-inositol-3 Kinase (PI3K). RA treatment rapidly activates the PI3K/Akt signaling pathway, which is a requisite for neuroblastoma cell differentiation, since treatment with PI3K specific inhibitor LY294002 impaired RA-induced differentiation. The results described here show evidence of novel actions of RA contributing to the induction of neural cell differentiation.
In addition, the activation of PI3K/Akt signaling pathway by RA gives support for a heretofore unrecognized role of RA on the regulation of survival in neural cells, that provides a link between cell differentiation and cell survival.
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EXPERIMENTAL PROCEDURES
Cell Culture and treatments.
SH-SY5Y human neuroblastoma cells were cultured in RPMI1640 medium with 10% fetal calf serum and 0.15 mg/ml gentamycin sulfate in a humidified incubator at 37ºC with 5% CO 2 . The medium was replaced every 3 days and the cells were split before they reached confluence. RA (all-trans retinoic acid), TPA (phorbol 12-myristate, 13-acetate), cycloheximide and LY294002 (all from Sigma) were dissolved in ethanol or DMSO and added to the culture medium at the indicated concentrations.
DNA probes
Most of the DNA probes were inserts from EST-containing plasmids obtained from IMAGE Consortium cDNA (24) . MYC probe consisted of a 1.3 Kb genomic fragment containing human MYC exon 3 (25) .
Probes for NPY, ACTB and PPIA were generated by RT-PCR from RNA from SH-SY5Y cells. NPY probe was a 403 bp fragment, including nucleotides 5-407 of NPY cDNA (26) . ACTB (actin beta) probe was a 183 bp fragment, encompassing nucleotides 287-470 of the ACTB cDNA (27) . PPIA (peptidylprolyl isomerase A, cyclophilin A) probe was a 415 bp fragment, including nucleotides 101-516 of the PPIA cDNA (28).
Northern Blot
Total RNA was obtained from PBS-washed cell monolayers by the method of Chomczynski and Sacchi (29) . RNA (15-20 µg per lane) was denatured, electrophoresed through 1% agarose-formaldehyde gels and transferred to nylon membranes (NytranN45, Schleicher and Schuell) following standard techniques. DNA probes were labeled at high specific activity with [α 32 P]-dCTP (Amersham-Pharmacia Biotech, spec.
act.>3000 Ci/mmol) by multiprime (RadPrime labeling system, Life Technologies). Hybridization was carried out overnight at 65°C according to Church and Gilbert (30) . Filters were washed with 0.5xSSC, 0.1% SDS, first at room temperature for 10 min, and then for 30 min at 65ºC. Membranes were exposed to X-ray films at -70ºC with intensifying screens.
Nuclear Run-on transcription assay.
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Cell monolayers were washed with PBS, and lysated in RIPA buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM NaF, 1% TritonX100, 1% Deoxycholate, 0.1% SDS, 1mM sodium orthovanadate, 10 µg/ml Leupeptin, 10 µg/ml aprotinin, 100 µM PMSF). The extract was cleared by centrifugation at 4ºC and the protein content was determined with a detergent-compatible BioRad DC protein assay. Equal amounts of extracts were loaded to acrylamide SDS-PAGE gels according to Laemmli (31) , and the electrophoresed proteins were electro-transferred to Nitrocellulose membranes (HybondECL, Amersham Pharmacia Biotech). Membrane was blocked with PBS, 0.1% Tween20 and 5% non-fat dry milk for at least 1 h. Membrane was incubated with the primary antibody in the above solution at 4ºC for 16 h. After washing with PBS-0.1% Tween20, the filter was incubated with horseradish peroxidase-conjugated secondary antibody in PBS, 0.1% Tween20 and 5% non-fat dry milk for 1 h at room temperature. Luminescent signal development with ECL (Amersham Pharmacia Biotech) was performed as recommended by the manufacturer. Filters were exposed to X-ray films in the dark. Antibodies against p110β subunit of PI3K, Akt, α-tubulin, ID1, ID2 and ID3 were purchased from Santa Cruz Biotechnology. 
Electric Mobility Shift assay (EMSA)
Cell pellets were frozen in liquid nitrogen and cells lysated in 10 mM HEPES, pH 7.9; 0.1 mM EDTA, 5% Glycerol, 400 mM NaCl, 1 mM DTT, 0.1 mM PMSF. The lysate was cleared by centrifugation and the protein content determined with the BioRad Protein assay. A double-stranded oligonucleotide E-box probe corresponding to the sequence present in the muscle creatine kinase enhancer was used for EMSA (MCKE; 5': TCGACCCAACACCTGCTGCCGTACCAGCT-3', the E-box sequence shown in bold characters). The (dI-dC) and 50x10 3 cpm of the labeled MCKE probe. After 10 min incubation, the samples were loaded to a 6% poly-acrylamide gel in 0.5xTBE, and the gel run at 300 V for 2 h at 4°C. Finally, the dried gel was exposed to X-ray films.
PI3K assay.
Cell monolayers were washed with ice-cold PBS, and cells were scraped off in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM NaF, 1mM sodium orthovanadate, 10µg/ml aprotinin, 10 µg/ml leupeptin, 0. 
RESULTS
The expression of ID bHLH transcription factors is downregulated during RA-induced differentiation of SH-SY5Y human neuroblastoma cells.
To characterize the molecular mechanisms through which RA triggers differentiation in SH-SY5Y cells, we analyzed differentially expressed genes using the Ordered Differential (Fig. 1D ).
RA treatment modified the expression pattern of bHLH transcription factors involved in neuronal differentiation.
ID proteins bind to and sequester ubiquitous E-proteins, avoiding complex formation with tissue-specific bHLH proteins and precluding heterodimer binding to E-box DNA elements.
Treatment of SH-SY5Y cells with RA resulted in an increase of the protein complexes bound to an E-box element in gel-shift experiments ( 
RA treatment of SH-SY5Y cells resulted in sustained activation of PI3K as demonstrated
by the corresponding in vitro kinase assay performed with total cellular extracts. (Fig. 5A ).
Treatment with RA for 24 h resulted in a four-fold increase in PI3K activity, which lasted up to 48 h. This increase was abrogated when the assay was performed in the presence of LY294002 (Fig. 5B ). This sustained increase of PI3K activity correlated with an increase in the levels of the catalytic subunit of the enzyme, p110β, as shown by western blot with specific antibodies (Fig.   5C ). This increase appears to be consequence of an effect of RA on the stability of the protein, since a parallel increase in p110β mRNA was not detected (data not shown). Akt kinase is one of the major targets of PI3K. Treatment of SH-SY5Y neuroblastoma cells with RA resulted in rapid phosphorylation of the Akt kinase in Ser473 (Fig. 5D ). inhibited by addition of LY294002 (Fig. 6A) . Treatment of the cells with the PI3K inhibitor resulted in a moderate increase in GAP43 mRNA basal level. However further transcriptional activation of GAP43 by RA was prevented by treatment with LY294002 (Fig. 6B ).
Transcriptional activation of the anti-apoptotic gene BCL2 was also impaired by treatment with LY294002 (Fig. 6C) . Transcription of BCL2 is strongly activated during RA-induced differentiation. Again a moderate increase of BCL2 mRNA basal level could be observed in LY294002-treated cells. However, the inhibitor prevented RA-induced upregulation of BCL2. 
